GlaxoSmithKline's (GSK) and partner San Raffaele Telethon Institute for Gene Therapy's recent positive European approval for Strimvelis for treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) represents the second EU-approved gene therapy and the first γ-retrovirus and first ex vivo gene therapy. In this article we discuss the significance and implications of this historic approval for the broader gene therapy field.
BoothC, GasparHB. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics: Targets & Therapy, 2009; 3:349–358.
4.
ChanB, WaraD, BastianJ, HershfieldMS, BohnsackJ, AzenCG, ParkmanR, WeinbergK, KohnDB. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clinical Immunology. 2016; 177:133–143.
5.
European Medicines Agency. Strimvelis opinion. www.ema.europa.eu (last accessed April27, 2016).
6.
AiutiA, CattaneoF, GalimbertiS, BenninghoffU, CassaniB, CallegaroL, et al.Gene Therapy for immunodeficiency due to adenosine deaminase deficiency. N Eng J Med, 2009; 360:447–458.
7.
GSK. GSK investor presentation. November3, 2015.
8.
European Medicines Agency. Reflection paper on management of clinical risks deriving from insertional mutagenesis. www.ema.europa.eu (last accessed April27, 2016).
9.
FiercePharma. GSK promises 'bubble boy' gene therapy will not break the bank as new pricing model revealed. www.fiercepharma.com (last accessed April27, 2016).
10.
Financial Times. GSK to allow staggered payments for EMA-approved gene therapy. www.ft.com (last accessed April27, 2016).
